DGAP-News: Neovacs S.A. / Key word(s): Conference
NEOVACS TO PRESENT AT BIO CEO & INVESTOR CONFERENCE
19.01.2015 / 18:30
---------------------------------------------------------------------
PRESS RELEASE
NEOVACS TO PRESENT AT BIO CEO & INVESTOR CONFERENCE
Paris, January 19, 2015 - NEOVACS (Alternext Paris: ALNEV), a leader in
active immunotherapies for the treatment of autoimmune diseases, announced
today that the Company will be presenting at the BIO CEO & Investor
Conference to be held in New York on February 9-10, 2015.
The 17th Annual BIO CEO & Investor Conference attracts over 750 investors
and takes place at the Waldorf Astoria, New York. A select number of
biotech CEOs are given the opportunity to introduce their companies,
technology and development programs.
Miguel Sieler, CEO of Neovacs, will present on February 9, 2015 at 9:30 am
E.T.
About Neovacs
Created in 1993, Neovacs is today a leading biotechnology company focused
on an active immunotherapy technology platform (Kinoids) with applications
in autoimmune and/or inflammatory diseases. On the basis of the company's
proprietary technology for inducing a polyclonal immune response (covered
by five patent families that potentially run until 2032) Neovacs is
focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy
being developed for the indication of lupus. Neovacs is also conducting
preclinical development works on other therapeutic vaccines in the fields
of auto-immune diseases, oncology and allergies. The goal of the Kinoid
approach is to enable patients to have access to safe treatments with
efficacy that is sustained in these life-long diseases.
For more information on Neovacs, visit www.neovacs.fr
Contacts
NEOVACS
Nathalie Trépo
+33 (0)1 53 10 93 00
ntrepo@neovacs.com
Press - Financial Communications- Publicis
Stéphanie Tabouis
+33 (0) 1 44 82 46 35 stéphanie.tabouis@consultants.publicis.fr
Investor Relations - Financial Communications Germany - MC Services
Raimund Gabriel
+49-89-210228-30
Raimund.Gabriel@mc-services.eu
Press - U.S. Inquiries - The Ruth Group
Melanie Sollid-Penton
1.646.536.7023
msollid@theruthgroup.com
---------------------------------------------------------------------
19.01.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Neovacs S.A.
3-5, Impasse Reille
75014 Paris
France
Phone: +33 (0)1 53 10 93 00
Fax: +33 (0)1 53 10 93 03
E-mail: www.neovacs.fr
Internet: info@neovacs.fr
ISIN: FR0004032746
WKN: A1CVKR
Listed: Freiverkehr in Stuttgart; Frankfurt in Open Market
End of News DGAP News-Service
---------------------------------------------------------------------
314653 19.01.2015
DGAP-News: NEOVACS TO PRESENT AT BIO CEO & INVESTOR CONFERENCE
| Quelle: EQS Group AG